NICE (UK): Xenpozyme (olipudase alfa) for treating acid sphingomyelinase deficiency type AB and type B is not recommended – Sanofi
NICE (UK): Olipudase alfa is not recommended, within its marketing authorisation, for treating acid sphingomyelinase deficiency (ASMD; Niemann–Pick disease) in people with type AB or type B. This… read more.
